Life science tools supplier Lumicks has appointed Andre Nel as Chief Financial Officer. He will be based in the company's headquarters in Amsterdam. Nel brings more than 20 years' experience providing strategic and operational financial support for global multi-billion-dollar organisations.
Most recently he served as CFO at Dante Labs, a provider of consumer genome sequencing testing services. Previously, he spent close to seven years with Illumina, ending as VP of Finance and a member of the global finance leadership team based in the US. In more than eight years with Pfizer, he served as Finance Director-Russian Federation, Global Transformation & European Decision Support Centre of Excellence Finance Lead and Head of Financial Planning and Reporting.
Olivier Heyning, CEO, Lumicks, said: "We are very pleased to attract an experienced life sciences financial executive like Andre to Lumicks at this pivotal point in our growth. His seasoned expertise across large, global life science companies, including Illumina and Pfizer, will be invaluable to us as we accelerate our growth worldwide. With our recent successful product launches and the increasing recognition our innovative technology is receiving as a critical tool in analysing core biological processes, Andre's financial expertise will enable us to achieve our growth plans and establish Lumicks as a leader within the life sciences industry worldwide."
Nel said: "I am excited to join Lumicks as it begins to expand its operations around the world. My expertise in working with life sciences companies on a global basis has prepared me well to build scalable operations that enable companies to achieve successful growth. I am confident that Lumicks is on the cusp of an accelerated growth trajectory, and I look forward to working with my colleagues there to establish a firm financial foundation to support that growth."
